Mycobacterium tuberculosis

From IDWiki
Mycobacterium tuberculosis /
Revision as of 09:43, 16 August 2019 by Aidan (talk | contribs)
  • Mycobacterium tuberculosis causes tuberculosis, most commonly pulmonary but can affect any organ

Classification

  • Primary vs. reactivation vs. reinfection
  • Latent vs. active

Epidemiology

  • Reinfection accounts for ~40% of active tuberculosis in endemic countries
  • Latent tuberculosis in ~30% of the global population

Presentation

  • Primary tuberculosis is usually asymptomatic
    • Possible presentations include mild URTI with cough and/or fever
    • May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
      • Ghon complex, especially in children
    • May progress in children and the immunocompromised patients
  • Recent primary tuberculosis
    • Immunological phenomena
      • Erythema nodosum
      • Phlyctenular conjunctivitis
  • Recent or active tuberculosis
    • Erythema induratum
  • Reactivation tuberculosis
    • Poorly-defined clinical course
    • Usually reactivates in lung apices
  • Active tuberculosis
    • Cough and fever for more than two weeks
    • Cough and HIV infection
  • Extra-pulmonary tuberculosis

Investigations

  • AM sputum for acid-fast bacilli x3
    • About 70% sensitive
  • ANTB (PCR)
    • About 75% sensitive

Management

  • Standard HREZ x2mo then HR x4mo
    • Isoniazid 5mg/kg/d, max 300mg daily
    • Rifampin 10mg/kg/d
    • Pyrazinamide 25mg/kg/d, max 2g daily
    • Ethambutol 20mg/kg/d, max 1.2g daily
    • Pyridoxine
  • Airborne precautions until:
    • Treated for at least 2 weeks
    • 3x negative sputum smears
      • Collected at 8- to 24-hour intervals, including one early morning collection
    • Improvement in symptoms

IRIS

DILI

  • Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  • Rif > INH > PZA
  • Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  • Procedure
    • Hold if ALT >120 and symptoms, if ALT >200 even without symptoms, or bili >2x ULN
    • Switch to second-line meds
    • Reintroduce the original drugs once AST & ALT are <2x ULN
    • Only rechallenge with pyrazinamide if it was a mild case

Adherence to Treatment